Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.
Chang-Myung OhSungsoo ChoJi-Yong JangHyeongseok KimSukyung ChunMinkyung ChoiSangkyu ParkYoung-Guk KoPublished in: Korean circulation journal (2019)
SGLT2 inhibitors have a protective effect in Dox-induced HF in mice. This implied that SGLT2 inhibitor therapy could be a good treatment strategy even in HF patients without diabetes.
Keyphrases
- heart failure
- high glucose
- end stage renal disease
- diabetic rats
- type diabetes
- ejection fraction
- acute heart failure
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- drug induced
- prognostic factors
- drug delivery
- stem cells
- oxidative stress
- endothelial cells
- metabolic syndrome
- patient reported outcomes
- glycemic control
- cancer therapy
- atrial fibrillation
- high fat diet induced
- climate change
- cell therapy
- smoking cessation
- cardiac resynchronization therapy